In a significant development for the medical community and those affected by Microvillus Inclusion Disease (MVID), stakeholders received promising news as the Shylicine™ patent has been allowed in the United Arab Emirates. This milestone marks a crucial step forward in the quest for effective treatment options for this rare genetic disorder.

The announcement, made by Vanessa Biotech, heralds a breakthrough in the field of medical research and innovation. The Shylicine™ patent not only addresses MVID but also encompasses intellectual property related to cholera and various other digestive diseases. Notably, the Kravtsov-Gray patent, under which Shylicine™ falls, has been filed in multiple jurisdictions, including the United States, Europe, and 10 other countries.

Expressing enthusiasm over this achievement, the message conveyed a sense of optimism and determination in the pursuit of regulatory approval. This latest success underscores the commitment of Vanessa Biotech to its overarching mission of bringing hope to individuals where previously there was none.

As stakeholders celebrate this milestone, anticipation grows for the official issuance of the patent, which is expected imminently. The approval of the Shylicine™ patent in the United Arab Emirates not only validates the efficacy of the treatment but also opens doors for broader accessibility and impact in combating MVID and related conditions.

This announcement marks a significant stride forward in the ongoing battle against rare diseases, offering renewed hope to patients and their families worldwide. Stay tuned for further updates as Vanessa Biotech continues its journey towards advancing healthcare and transforming lives.

As the curtain falls on 2023 and Vanessa Biotech prepares to mark its 10th year milestone, reflections on the journey thus far evoke a sense of pride and optimism. From humble beginnings to a decade of innovation, the company’s trajectory has been marked by numerous small victories, underpinned by a commitment to solid science, groundbreaking intellectual properties, and unwavering perseverance in the face of adversity.

With ongoing clinical trials addressing critical medical challenges such as Microvillus Inclusion Disease, Cholera, Crohn’s Disease, and Ulcerative Colitis, the horizon remains promising for Vanessa Biotech. These endeavors symbolize not only a dedication to scientific advancement but also a profound commitment to improving global healthcare outcomes.

Looking ahead to 2024, the management team anticipates a turning point as Vanessa Biotech aims to transition from a zero-revenue entity to one generating revenue. This transformation, anticipated to be fueled by potential regulatory approvals for one or both of the company’s drug candidates, holds the promise of a significant breakthrough and a fitting celebration of a decade of dedication and innovation.

The message extends heartfelt gratitude to stakeholders whose unwavering support has been instrumental in the journey. Their role in shaping an extraordinary community dedicated to advancing healthcare solutions is acknowledged with deep appreciation.

From the frontline teams spanning Hungary, Spain, and the USA, warm wishes for a happy and prosperous New Year are extended to all. As we embarks on the next chapter of its journey, the collective spirit of hope and determination propels it forward towards a future marked by continued innovation, collaboration, and impactful achievements.

Join Vanessa Research in celebrating a decade of progress and looking ahead to a promising 2024!

Vanessa Biotech is pleased to announce the progress of its clinical trial in Bangladesh. This update marks a crucial step forward in the journey towards potentially life-changing treatments.

The drug, which has been certified and is now en route to Bangladesh, represents a culmination of dedication and collaboration among teams spanning the USA, Spain, and Hungary. Their tireless efforts have ensured the smooth progression of this pivotal trial, underscoring Vanessa Biotech’s commitment to advancing healthcare solutions worldwide.

With the trial now entrusted to the esteemed International Center for Diarrheal Research, Bangladesh (icddr,b), anticipation mounts for the investigation to commence in-country. The icddr,b’s renowned expertise and reputation as a global leader in diarrheal disease research position it as a fitting partner for this critical phase of the trial.

To learn more about the icddr,b and its impactful work, visit their website at www.icddrb.org.

The announcement reaffirms the collective hope and determination driving Vanessa Biotech’s mission to address unmet medical needs and improve patient outcomes. As the trial progresses, stakeholders are encouraged to reach out with any questions or inquiries, further fostering transparency and engagement in this transformative endeavor.

With optimism abound, Vanessa Biotech remains steadfast in its commitment to pioneering breakthrough treatments and bringing hope to individuals worldwide.

Stay tuned for further updates as the clinical trial unfolds and the journey towards impactful healthcare solutions continues.

Hope is Alive!

Excitement abounds as Vanessa Biotech announces a significant milestone in its journey towards regulatory approval, particularly for its cholera candidate, AD-1005. This achievement marks a crucial step forward in the quest to address severe diarrhea caused by cholera and other related conditions.

On Sunday morning, October 29, 2023, the Regulatory Director, Adel Egri, received the long-awaited notification of final approval from the People’s Republic of Bangladesh’s Directorate General of Drug Administration. This approval paves the way for the commencement of Phase 2 Clinical Trial for AD-1005, the novel antidiarrheal drug developed by Vanessa Biotech.

The trial will be conducted in collaboration with the esteemed International Center for Diarrheal Research, Bangladesh (icddr,b), a partnership that underscores the global significance of this research endeavor.

AD-1005 represents a groundbreaking approach to the treatment of severe diarrhea associated with cholera. It is intended to address the urgent need for effective interventions against cholera, rotaviral diarrhea, and traveler’s diarrhea. Unlike other antidiarrheal medications, AD-1005 is designed to reduce the volume of liquid stool produced by the intestine without affecting its motility or inducing constipation. If successful, AD-1005 will mark a significant breakthrough as the first symptomatic medication to treat severe secretory diarrhea.

This achievement is a testament to the dedication and perseverance of the entire team at Vanessa Biotech, who have worked tirelessly against formidable challenges over the past two years. Their unwavering commitment and tireless efforts have brought this milestone to fruition, underscoring the collective determination to advance medical science and improve patient outcomes.

As Vanessa Biotech celebrates this achievement, the message resounds clear: “Hope” is alive and well. The approval of AD-1005’s Phase 2 Clinical Trial in Bangladesh signals a new chapter in the fight against cholera and offers renewed hope for those affected by this debilitating condition.

Cheers to the entire team at Vanessa Biotech for this remarkable achievement, and here’s to the promising future that lies ahead.

The first shipment of Shylicine intended for the UAE Clinical trial is now, officially, on the way to Dubai.

This is a significant accomplishment for our team and evidence of our capacity to quickly reproduce a high-quality drug for human ingestion.

We congratulate the entire team in Spain, Hungary and the US for a job well done despite these extremely trying times.

Prof. Kenu said in his report report dated 02/12/2022:

“I wish to inform you of the successful recruitment of the first (1st) case at the Kekele Polyclinic yesterday and patient consented to participate in the study and being managed per the study protocol.”

The trial is a double-blind study which means that we do not know if they were given a placebo or our AD-1005, a novel antidiarrheal investigational drug, for Phase II clinical trial with the Pan African Clinical Trials Registry for treatment of severe diarrhea of cholera. nevertheless, our best wishes go to the patient and the family.

This is a momentous milestone with about four months from the start of 2022 rainy season and 299 patents more patients needed to conclude the study.

Vanessa Biotech (VB), a Hamden, Conn.-based biomedical company committed to improving patient quality of life by developing innovative solutions for unmet medical needs, filed a patent application for the novel and promising treatment of inflammatory bowel disease.

The patent was filed on February 20 as a patent cooperation treaty countries (PCT) application, allowing to streamline the intellectual property (IP) protection process and to pursue IP protection in any and all of 155 member states of the treaty.

Inflammatory bowel disease (IBD) is a significant problem affecting developed countries. One of the main symptoms of the disease is diarrhea. IBD is a chronic condition which persists for years and has a huge impact on the quality of life of people suffering from it.

VB believes that efficient and safe medicine for abdominal symptoms of IBD is much needed and will help individuals to better cope with the disease. VB has been developing treatments that address lethal secretory diarrheal diseases under the direction of Dr. Dmitry Kravtsov, VP of Research and Development. “This patent application is a significant step forward for us on our pathway of introducing efficient solutions for patients suffering from IBD,” said Dr. Kravtsov.

About Vanessa Biotech

Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.

Contact Information
Vanessa Biotech
P.O. Box 185755

Hamden, Conn.  06518 USA

+1 203 836 8424

Contact Us

Vanessa Biotech (VB), a Hamden, Conn.-based biomedical company committed to improving patient quality of life by developing innovative solutions for unmet medical needs, proudly supported Rare Disease Day for the fifth consecutive year. 

Rare Disease Day is observed internationally each year on the last day of February, because that day is viewed as the rarest day of the year. The aim of the day is to raise awareness regarding the 300 million people worldwide who are battling rare diseases. Rare Disease Day was first launched internationally by EURORDIS and its Council of National Alliances in 2008. National Organization for Rare Disorders (NORD) became the official US sponsor of Rare Disease Day in 2009. A Vanessa Biotech social media campaign kicked off during February 2022 to help shine a light on rare disease worldwide, and to raise awareness for EURORDIS-Rare Diseases and NORD. The campaign included highlights from rarediseaseday.org and an invitation for employees to join the NORD’s Rare Disease Day event on February 28th. VB currently has orphan drug designation through the European Medicine Agencies for Shylicine™ its candidate for treating MVID; Shylicine™ is currently in a Phase 2 clinical trial.

About Vanessa Biotech

Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.

Contact Information
Vanessa Biotech
P.O. Box 185755

Hamden, Conn.  06518 USA

+1 203 836 8424

Contact Us

Ghana FDA grants final approval to Vanessa Biotech for Phase II clinical trials for VR-AD-1005, a novel antidiarrheal investigational drug, for treatment of severe diarrhea of cholera.

Vanessa Biotech, the Hamden, Conn. based global biomedical company dedicated to making an impact on healthcare markets, has been granted regulatory approval from the Ghana FDA to conduct Phase II clinical trials for VR-AD-1005, a novel antidiarrheal investigational drug.

The Phase 2 study will be conducted during the current rainy season by the University of Ghana’s research team lead by Prof. Ernest Kenu as Principal Investigator. The team had its kickoff meeting on August 12, 2021, and is now in full preparation mode for the trial to begin recruiting patients.

The drug will be studied for the innovative treatment of severe diarrhea of cholera, heralding a pipeline of drugs developed in hopes of neutralizing the lethal diarrhea of cholera as well as rotaviral diarrhea and traveler’s diarrhea.VR-AD-1005 is intended to work by reducing the volume of liquid stool produced by the intestine when suffering from the diarrheal pathogen. The drug works within the intestine without affecting its motility and does not induce constipation. If successful—unlike other antidiarrheal medications—VR-AD-1005 will be the first symptomatic medication to treat severe secretory diarrhea.

“The company is currently amid its first external capital Raise” commented CFO Don Janezic, “And beginning this Phase 2 trial is a significant milestone in the company’s quest to be major player in the anti-diarrheal space.”

* These claims are based on preclinical studies and observed results in clinical trials to date. As clinical trials have not been completed, there can be no definitive proof these claims will ultimately be proven to be factual.

About Vanessa Biotech

Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.

Contact Information
Vanessa Biotech
P.O. Box 185755

Hamden, Conn.  06518 USA

+1 203 836 8424

Contact Us

Vanessa Biotech registers VR-AD-1005, a novel antidiarrheal investigational drug, for Phase II clinical trial with the Pan African Clinical Trials Registry for treatment of severe diarrhea of cholera.

Vanessa Biotech, the Hamden, Conn. based global biomedical company dedicated to making an impact on healthcare markets, has registered VR-AD-1005, a novel antidiarrheal investigational drug, with the Pan African Clinical Trials Registry (PACTR) system, as of June 21, 2021. The drug will be studied for the innovative treatment of severe diarrhea of cholera, heralding a pipeline of drugs developed in hopes of neutralizing the lethal diarrhea of cholera as well as rotaviral diarrhea and traveler’s diarrhea. VR-AD-1005 is intended to work by reducing the volume of liquid stool produced by the intestine when suffering from the diarrheal pathogen. The drug works within the intestine without affecting its motility and does not induce constipation. If successful—unlike other antidiarrheal medications—VR-AD-1005 will be the first symptomatic medication to treat severe secretory diarrhea. “Our unique approach to treatment of diarrhea concentrates on solving the problem of continuous removal of antidiarrheal medications with enormous volume of stool in patients suffering from acute watery diarrhea. This problem is known as convective washout, and it is recognized as the major factor limiting efficacy of oral antidiarrheal medicines. Vanessa Biotech is the first company that has developed a solution for it,” according to Dr. Dmitry Kravtsov, Vice President of Research and Development at Vanessa Biotech.

* These claims are based on preclinical studies and observed results in clinical trials to date. As clinical trials have not been completed, there can be no definitive proof these claims will ultimately be proven to be factual.

About Vanessa Biotech

Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain and Germany in addition to its Hamden, Conn. corporate campus.

Contact Information
Vanessa Biotech
P.O. Box 185755

Hamden, Conn.  06518 USA

+1 203 836 8424

Contact Us

Stay connected

Subscribe to receive updates on our research, product development, and new initiatives.


You have the right to withdraw your consent by unsubscribing at any time.